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Abstract: Diabetes has become a leading cause of death worldwide. Although there is no cure for
diabetes, blood glucose monitoring combined with appropriate medication can enhance treatment
efficiency, alleviate the symptoms, as well as diminish the complications. For point-of-care purposes,
continuous glucose monitoring (CGM) devices are considered to be the best candidates for diabetes
therapy. This review focuses on current growth areas of CGM technologies, specifically focusing
on subcutaneous implantable electrochemical glucose sensors. The superiority of CGM systems is
introduced firstly, and then the strategies for fabrication of minimally-invasive and non-invasive
CGM biosensors are discussed, respectively. Finally, we briefly outline the current status and future
perspective for CGM systems.
Keywords: continuous glucose monitoring; glucose biosensor; implanted devices; mini-invasive;
non-invasive
1. Introduction
Diabetes mellitus is a worldwide epidemic disease affecting 422 million people, and is predicted
to be the seventh leading cause of death if the current morbidity trends continue [1]. Blood glucose
(BG) concentrations in diabetics can undulate significantly throughout a day, and they lead serious
consequences including kidney failure, strokes, heart attacks, high blood pressure, blindness and
coma [2,3]. BG levels could be finely controlled by insulin, and the abnormal concentration of BG is
caused by the absence of insulin secretion (type I diabetes, T1D) or defective insulin secretion and action
(type II diabetes, T2D). For maintaining BG within the euglycemic range, the BG concentration should
be detected at least twice a day and four times a day for T2D patients and T1D patients, respectively,
and combined therapies including drugs, exogenous insulin supply, diet and physical exercise [4–6].
The emergence of glucose sensors has provided patients the ability to self-monitor BG levels so as to
manage insulin levels, and thus control the mortality of diabetes mellitus. Traditional glucose detecting
devices primarily consist of glucose sensors based on electrochemical methods [7]. The frequent
analysis of BG levels requires a small blood sample (<1 µL) obtained by a “finger-pricking” collection
method, which is inconvenient and results in poor patient compliance. Such tests neglect nighttime
variations and might cause approximation of BG variations. Moreover, instantaneous monitoring
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sensors cannot provide real-time BG information, and thus are unable to warn of hypoglycemic
(low blood sugar, <3.0 mM) and hyperglycemic (high blood sugar, >11.1 mM) events in advance.
There are three generations in the development of glucose biosensors, the first-generation relied
on the use of the natural oxygen and the production-detection process of hydrogen peroxide, and the
second-generation sensors employ a non-physiological electron acceptor to shuttle electrons and thus
solve the oxygen deficiency. The market leading methods are based on second generation sensor
technology. The design of the third-generation glucose sensors aims to get rid of the leachable artificial
mediators and even the glucose enzyme. Therefore, continuous glucose monitoring (CGM) devices are
considered to be the ideal candidate for the next generation products to replace the currently used portable
glucose meters [8]. CGM reports BG levels as trends of glucose fluctuations during a day (including the
increasing or decreasing of BG), and these data could be utilized for various applications, including
retrospective analysis [9], hypo/hyperglycemia detection and prediction [10,11]. Ideally, intelligent
CGM devices could be linked to an insulin delivery pump to form an artificial pancreas [12], and the
benefit of CGM point-of-care tests for the self-management of diabetes patients is the reduced time
length spent in hypoglycemia and the increased time in euglycemia [13–15]. However, the current
gold standard glucose biosensors are invasive, and CGM systems still present a number of limitations,
such as biofouling, fibrous encapsulation of the implanted electrode, inflammation, and loss of host
vasculature, which seriously affect the precision and accuracy of the BG results [16]. Non-invasive
methods, on the other hand, are increasingly prevalent due to the highly sensitivity and better patient
compliance contrary to invasive ones [17]. Since there is a delay as glucose is transported from the
blood level to the interstitial fluid level, the real-time information detected from CGM sensors might
be 15–20 min later than BG, so the lag-of-time of interstitial glucose (IG) relative to BG limits the
result reliability in hypoglycemic emergency situations. Although, many enhancements have been
implemented to mitigate the inaccuracy of CGM, there is still lack of approval of CGM data for
adjusting insulin, since the dosage of insulin is strongly dependent on the BG level and rate of change
of BG. Another barrier is the lifetime of the sensors, as loss of function happens to most implantable
electrodes within 7 days, and the calibration would also create a series of problems such as cost, toxicity,
inconvenience and discomfort [18]. The integration of CGM with wireless devices could be an effective
method for developing closed loop systems like the Internet of Things. By 2017, there will be more
mobile phones around world than people, and the CGM data could be sent to the smart phones for
analysis to then trigger the release of drugs [19].
This review focuses particularly on the progress in the development of CGM technologies,
focusing specifically on subcutaneous implantable electrochemical glucose sensors, which are widely
studied and commercially available. We briefly introduce the superiority of CGM systems and discuss
the challenges in the development and implementation of CGM devices in Section 1. Strategies for the
fabrication of minimally-invasive CGM biosensors, including new materials, biocompatible coatings
and drug delivery systems, are presented in Section 2. The non-invasive technologies and concepts are
introduced in Section 3. Finally, we briefly outline the current status and future perspectives for CGM
systems in Section 4.
2. Mini-Invasive Biosensors for CGM
Dynamic glucose detection methods usually employ a tiny sensor inserted beneath the skin and
maintained for a certain period of time in contact with the interstitial fluid. Most minimally-invasive
systems for CGM are enzyme-based, whereas others are enzyme-free. For both enzyme and non-enzyme
methods, numerous efforts have been focused on the preparation, functionalization and modification of
the required electrodes [16,20,21].
2.1. Sensing Design and New Materials
Enzymatic electrodes use enzymes to catalyze reduction–oxidation (redox) reactions, and the
movement of electrons could thus produce a concentration-dependent current or voltage that
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can be measured by electrodes. Frequently utilized electrodes for invasive sensor technology
include microdialysis, micropores, microneedles, subcutaneous amperometric electrodes, and
intravenous implantable devices. Currently, only microdialysis and subcutaneous devices have reached
commercialization. Microdialysis systems utilize a hollow microdialysis fiber which is perfused
with isotonic fluid from an ex vivo reservoir, and meanwhile IG freely diffuses into the fiber, and
then is pumped to an enzyme-based electrochemical sensor. This system has smaller dimensions
for implantation convenience, and the sensor is ex vivo, thus avoiding biofouling problems [22].
For subcutaneous methods, the design of the electrodes mainly aims at increasing the sensitivity,
selectivity and biocompatibility.
A major historical advance in the in vivo application of glucose biosensors was the classic
needle-type sensor, which generally consists of a platinum-iridium (Pt-Ir, φ 0.125 mm, Pt:Ir = 9:1))
wire working electrode with an immobilized mediator and enzyme on the surface, and/or a polymer
coating for subcutaneous implantation. A silver/silver chloride (Ag/AgCl) wire is wrapped around the
working electrode that serves as a counter electrode. Such devices are designed for human implantation
sensors that continuously operate for a few days and be replaced by the patient. Algorithm correction
for the transient differences (lag-time) between BG and IG concentrations have been investigated for
future applications. Kumetrix (Union City, CA, USA) has proposed a hand-held, battery-powered
electronic monitor with silicon micro-needles that are similar in size to a human hair. The aim is to
develop a meter system that accepts a cartridge loaded with disposable sampling devices. This action
will cause the micro-needle to penetrate the skin and draw a very small volume of blood (less than
100 nL).
Coil-type oxidase biosensors were developed based on the design of needle-type ones. Pt-Ir wire was
wound up along a 30-gauge needle to form a coil-shaped cylinder, which had a length of ca. 1 mm with
an outer diameter of 0.55 mm and an inner diameter of 0.3 mm. Such a design dramatically increased
the sensing area of flexible implantable biosensors within an acceptable length range and created a ca.
0.07 mm three inner storage chamber for extra enzyme immobilization. With modifications such as
etching of the surface of coil, hydrogel layer coatings and loading with certain drugs, the constant
response of the sensor could be maintained for at least 60 days [23].
As for commercialized glucose sensors, Abbott (Chicago, IL, USA) has developed a series of
BG monitoring products named FreeStyle since June 2000. A recent FreeStyle Libre device allows
patients to measure glucose within 1 s by scanning the sensor with a reader, and the sensor could work
for 14 days without calibration. As a result, the pain associated with testing is greatly reduced. In 2006,
the Dexcom (San Diego, CA, USA) SEVEN, the first real-time continuous glucose monitoring system,
was approved by the FDA. Recently the Dexcom G5, the first fully mobile CGM system, was launched.
Dynamic glucose data could be accessed safely by a compatible smart device. Another transdermal
implantable CGM system, the CT-100 (POCTech, Huzhou, China), utilizes a “parallel implant method”,
which offsets the limitation of the length of the sensor by taking full advantage of the subcutaneous
tissue and thus differs from Dexcom’s products. Such a design improves the sensitivity while
preventing misoperation causing the sensor to go into the muscle tissue.
The diagnosis and management of diabetes mellitus require a tight monitoring of glucose
concentration. An ideal sensor would be one that provides reliable real-time continuous monitoring of
glucose variations throughout the day with high selectivity and speed over extended periods under
harsh conditions. New sensing concepts, coupled with new materials and numerous technological
innovations have been made for enhancing the capabilities and improving the reliability of glucose
measuring devices.
The development of carbon nanotubes (CNTs) and graphene-based electrodes have been
intensively studied, and they show good safety when used in implantable electrodes for in vitro
testing [16]. With similar dimensions as redox proteins, carbon nanomaterials could be utilized as
effective electrical wiring/connectors with redox enzymes, which is one of the most promising materials
for enzymatic glucose biosensors. For bio-sensing applications, graphene and CNTs demonstrated
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higher sensitivity and faster response time than traditional electrodes at extremely low working
potentials. Our group has carried out a comprehensive study of CVD-synthesized CNT fibers used as
sensing electrodes to detect glucose solutions. The CNT fiber resembles an electric wire, relying on
nanoscale surface topography and porosity, which can facilitate molecular-scale interactions with
agents like enzymes to efficiently capture and promote electron transfer reactions [24,25]. A scalable
synthesis of a multifunctional conducting polyacrylic acid (PAA) hydrogel for glucose detection that
integrates a multifunctional matrix that includes reduced graphene and lutetium phthalocyanine was
reported. This biosensor provided high sensitivity for the detection of glucose with a low detection
limit [26]. However, better control of the physical and chemical properties is still needed for the
fabrication of carbon nanomaterial-based biosensors, such as the miniaturization of the sensor, in vivo
stability, separation processes for different type of CNTs, etc. Other non-enzymatic sensors, such as
metallic oxide and strontium palladium perovskite also show enhanced sensitivity and improved
detection limits, and thus avoid the need for expensive enzymes in the system [27,28].
Microgels, glucose-responsive polymer gels, have several advantages as glucose sensing systems
due to their porous structures for carrying drugs, semi-solid properties for easy engineering into
various shapes (beads, films, fibers, etc.), and potential biocompatibility for implantation. Since the
first preparation of boronic acid-functionalized glucose sensitive hydrogels [29], many polymer
gel-based glucose sensors have been developed based on the measurements of swelling pressure [30],
fluorescence intensity [31], changes in reflection holograms [32,33] and diffraction of photonic colloidal
crystal arrays [34]. Li et al. recently developed a series of inorganic-polymer hybrid microgels for optical
glucose sensing, based on the immobilization of fluorescent quantum dots (QDs) or metal nanoparticles
(NPs) into phenylboronic acid (PBA)-functionalized microgels [35]. Zhang et al. constructed an advanced
glucose-sensitive platform on the basis of G1.0 PAMAM-functionalized microgels [36]. The beauty of
this smart microgel, which differentiates it from other examples of traditional glucose sensors, is that
it provides minimally invasive implantation and a fluorescent signal by transdermal transmission
without any external links or electric power sources for CGM. A schematic illustration of G1.0
PAMAM-functionalized microgels that can recognize glucose and emit blue fluorescence after injection,
is depicted in Figure 1.
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Figure 1. The schematic illustration of G1.0 PAMAM-functionalized microgels that can recognize
glucose and emit blue fluorescence after injection. Reprinted with permission from [36].
Semiconductor quantum dots (QDs), as photoluminescent nanomaterials, have been intensively
studied in sensing and cell imaging due to their excellent performance and size-tunable optical
properties [37]. Glucose could be detected by indirect measurements using photoelectrochemical
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QD sensors if combined with suitable enzymes [38,39]. Tanne et al. reported the indirect sensitive
detection of glucose by creating a signal chain from glucose via glucose oxidase and molecular oxygen
via CdSe/ZnS QDs toward the electrode [40], as shown in Figure 2. On the basis of the influence that
the oxygen concentration has on the photocurrent, the enzymatic activity of glucose oxidase catalyzing
the oxidation of glucose by the reduction of O2 was evaluated. During illumination, the photocurrent
was reduced as a result of the oxygen consumption. The sensing properties of this type of electrode
were strongly influenced by the amount of enzyme on top of the QD layer, which was found to be
easily adjustable using the layer-by-layer technique. The aforementioned glucose sensors are based
on signal chains of glucose-glucose oxidase-oxygen-QDs. However, the enzyme can also be coupled
to an electrode by means of a shuttle molecule, which facilitates a mediated electron transfer from
the biocatalyst. Zheng et al. constructed a photoelectrochemical electrode by alternately depositing
water-soluble CdSe-CdS QDs and a mixture of [Co(phen)3]2+/3+ and poly(ethyleneimine) on a TiO2
electrode [41]. In this setup, the electrode was able to transfer charge carriers from the reduced enzyme,
so that the obtained photocurrent depended on the concentration of glucose.
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Nowadays, label free and real time optical detection methods are the most promising techniques in
glucose monitoring. Complementary metal oxide semiconductor (CMOS) image sensore are becoming
powerful tools for biosensing applications with the advantages of high signal to noise ratio, low power
consumption, miniaturization and availability on smartphones and even easier to incorporate into
compact medical diagnostic devices. In addition, CMOS image sensors can employ various glucose
monitoring methods, including continuous glucose monitoring methods [42,43], enzymatic glucose
monitoring methods [44,45], and thermal-based glucose monitoring [46], to operate at the in vitro and
in vivo level.
Kim et al. exploited a CMOS image sensor for detecting glucose levels by simple photon count
variation with high sensitivity [44], as shown in Figure 3. Various concentrations of glucose (100 mg/dL
to 1000 mg/dL) were added onto a simple polydimethylsiloxane (PDMS) chip and the oxidation of
glucose was catalyzed with the aid of an enzymatic reaction. Oxidized glucose produces a brown
color with the help of a chromogen during the enzymatic reaction and the color density varies with
the glucose concentration. Photons pass through the PDMS chip with varying color density and hit
the sensor surface. Photon count was recognized by the CMOS image sensor depending on the color
density with respect to the glucose concentration and it was converted into digital form. By correlating
the obtained digital results with glucose concentration it is possible to measure a wide range of BG
levels with great linearity based on the CMOS image sensor and therefore this technique could promote
a convenient point-of-care diagnosis method.
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2.2. Novel Biocompatible Coatings for Sensors
The major challenge in the design of tissue-contacting materials for both bioaffinity and
medical implantation sensors is to endure protein adsorption between surfaces and interfaces.
Most minimally-invasive biosensors are surrounded by protective coatings that can strongly interact
with proteins, thereby minimizing tissue reactions induced by device implantation [47]. To achieve
a protein-resistant surface, the structure design of the anti-fouling material should be hydrophilic,
electrically neutral, and contain hydrogen bond acceptors instead of donors. These requirements
guide the design of anti-fouling formulations for sensing applications with novel structures that have
non-specific protein resistance [48]. A considerable number of effective candidates have been identified,
including organic/inorganic composites and biofunctional polymer architectures. Sol-gel derived
silicates have been demonstrated to be highly compatible with enzymes [49]. Silica-based hybrid
materials exhibit a fair biocompatibility both in vitro and in vivo, and are shown to be non-toxic and
biocompatible coatings for glucose oxidase-based sensors. Stable glucose responses were obtained for
the silica-polymer coated sensors both in buffered solutions containing bovine serum albumin and in
serum [50,51]. Unfortunately, the anti-fouling properties of such systems were not discussed.
Various macromolecules, including natural, semi-synthetic, and synthetic materials are currently
utilized in the fabrication of implantable CGM sensor coatings (cf. Table 1). Naturally occurring materials
such as alginate, chitin, and chitosan and their derivatives are widely investigated for biosensors in
the form of sheets, membranes and coatings, which offer the advantage of being comparable to
the natural precursors and the biological environment is prepared to recognize and deal with their
metabolites [52,53]. On the other hand, modified synthetic polymers with tailored structures and
coating properties are often superior to traditional macromolecules, especially for their reduced
immunogenicity. Commonly used biocomparable and biodegradable polymers includes poly(lactic
co-glycolic acid) (PLGA), poly(ethylene glycol) (PEG), poly(hydroxyethyl methacrylate) (PHEMA),
and poly(vinyl alcohol) (PVA), etc. [54]. Among the abovementioned polymers, HEMA-based materials
constitute the first generation of efficient protein-resistant materials while PEG-derived materials
represent the second generation [55]. Currently, they are extensively utilized in various areas and
can be used to modify mini-invasive devices by the coating method. They are also very popular as
hydrogel matrices, either alone or combined with other polymers [56].
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Table 1. Biochemical aspects of commonly used polymers.
Polymer Characters Formation Applications
Natural
Alginate Immobilization of glucose oxidase Hydrogel and membrane Drug delivery
Collagen Extracellular matrix component Hydrogel, membrane and sponge Scaffolds
Semisynthetic
Chitin,
Chitosan Hydrogel, membrane and fiber Anti-microbial and drug delivery
Synthetic
PLGA Negligible protein adsorption Micelle and hydrogel Coating, drug delivery and scaffolds
PHEMA Negligible protein adsorption Hydrogel Coating
PVA Geltaion and mechanical properties Hydrogel, membrane and sponge Coating and drug delivery
PEG Negligible protein adsorption Hydrogel and membrane Coating and drug delivery
PEGMA Negligible protein adsorption Hydrogel Coating
Hydrogels are hydrophilic, water-insoluble three-dimensional polymeric networks represented as
semi-open structures comprising entangled chains, which adsorb and store large amounts of water and
are highly permeable to small molecules. The use of hydrogel coatings allows the diffusion of glucose
through the swollen hydrogel layer. The degree of glucose diffusion could be readily modulated by
physically/chemically control of the cross-linking density of the hydrogel, which consequently affects
the water content and mechanical strength of polymer network. Both in vitro and in vivo animal
tests have demonstrated better performance with biocompatible polymer hydrogel outer layers for
a mini-invasive needle-type glucose sensor.
Despite oxidation problems that could alter the anti-fouling properties during long-term usage,
PEG-derived anti-fouling matrices remain popular and have been widely investigated [57]. Similar to
PEG, poly(ethylene glycol) methyl ether methacrylate (PEGMA) and PEGMA-analogous hydrogels
were also investigated for the design of the next generation of anti-biofouling materials [58]. The results
revealed that the molecular weight of the PEGMA homopolymer directly affected the overall
hydrophilicity of the gel, which could be attributed to both the intermediate hydrophilic chain length
and intermediate crosslinking degree. Furthermore, the results of micro-biofouling by bacteria and
blood cells demonstrated that PEGMA hydrogels offered the perfect non-fouling ability, showing
application potential for the coating of devices in contact with blood and the in vivo controlled release
of drugs from nonfouling hydrogels.
2.3. Drug Deliver and Its System
Drug delivery is a potential field of application for CGM devices [59]. In recent years, architectures
for sustained and controlled delivery of drugs has been extensively studied due to several problems
in common drug delivery systems, such as limited stability, inopportune leakage and poor solubility,
especially for CGM systems. Modern closed-loop BG controlling systems have been developed by
various organizations around the world, by merging glucose-sensing devices and insulin-delivery
carriers for optimized dosage of insulin according to detected glycemic levels (Figure 4). Such BG
management systems utilize a ‘Sense and Act’ feedback-loop design to realize appropriate corrective
action by timely and optimal dosing. The pump dispenses the right amount of insulin as the sensor
relays the information. The development of these responsive drug delivery systems is anticipated to
dramatically change diabetes management and patient monitoring. It is expected that the release of
different drugs could be controlled by a microprocessor in response to the signal from a biosensor via
different release kinetics.
Based on the biocoating, intelligent drug releasing functionality was also investigated to make
the system more integrated, and ensure the long-term usage of the device [60]. For instance, a PLGA-
copolymer, PVA and PEG combined system which has been shown to achieve a continuous release of
dexamethasone for up to one month that decreases extravasation of leukocytes, and inhibits production
of proteolytic enzymes and chemoattractive factors was already discussed [61,62]. A masitinib-releasing
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PLGA carrier delivers locally from soluble PEG-coated CGM sensors were developed to reduce the
host-implant response. The releasing action could be attributed to the CGM sensor output fluctuations
over time, which was monitored for 21 days. The results showed relatively improved performance in
terms of sensing ability in the drug-delivery implant group compared to the control group [63].
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for optimized insulin delivery.
Recently, a novel implantable electrochemical sensor was fabricated by utilizing a spiral Pt-Ir
alloy electrode to increase the active ar a of the working electrode as well as en ance the load ng of
glucose oxid se on the biosensor. The result showed that the sensitivity of the as-prepared spiral s nsor
was 20 nA/(mmol/L)~30 nA/(mmol/L), which provided a linear detection of physiological glucose
concentrations between 2 and 30 mmol/L. The sensors also showed good repeatability, selectivity, and
stabil ty, which c uld be tuned by adjusting the amount of the polyurethane (PU) semi-permeabl
membran coating [64]. More rec ly, the PU coating was further modified by a PVA-PEG hydrogel
t at enabled ze o-ordered release of dexamethaso e, and the release duration was controlled as
function of film gelation density. The umulative released amount could be adjusted by changes in
the molecular weight of the PEG. As a matter of fact, PEG derivatives were revealed to be effective
candidates for sensor coatings as well as controlled release of supposed drugs [58,65].
3. Non-Invasive Technology
Non-invasive techniques have received significant research interest due to the highly sensitivity
and better patient compliance, contrary to invasive ones. Typical non-invasive biosensors based on
different approaches include iontophoretic extraction of glucose through the skin, surface plasmon
resonance, Raman spectroscopy in aqueous humor, visible or near-infrared (NIR) spectroscopy,
polarimetry, photo-acoustic probes, and fluorescence methods. Although results from these innovative
devices require frequent calibration against direct BG data, they might be an alternative choice for
future continuous glucose measurement. Consequently, the challenge of preparing accurate level
sensors to bio onitor conveniently and painlessly BG information remains to be solved.
3.1. Tear Sensing Designs
Non-invasive, contact lenses are one of the most appealing ways to achieve constant contact with
tear fluid and monitor glucose in tears. Such a method could be used for normal conditions as well
as for clinical trials. During the course of treatment, the glucose could be continuously monitored.
Contact lenses have to meet a certain number of criteria, and should be made of soft, comfortable
materials with constant mechanical properties such as hydrogels or plasticized polymers that could
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withstand the eye movements and blinking. Moreover, the lenses also should be non-toxic and to allow
for a certain amount of oxygen and tear fluid to pass through to the eye. Some interactions between
contact lenses and the tear film were discussed. The presence of the contact lens immediately provides
the potential for both biophysical and biochemical phenomena. The biophysical phenomena resulting
from lens-tear interactions are often directly observable as the increased osmotic pressure caused by
enhanced evaporation of the tear film. The biochemical outcomes revealed the difference in electrolyte
concentration between the anterior and posterior tear films [66,67].
Several types of sensors have emerged in recent years based on different monitoring methods,
including electrochemical and spectral determination. Electrochemical sensors have become more
complicated and miniaturized at the same time. A protocol consisting of a soft polymer lens covered
by an enzyme-based sensor was reported, using a tiny metal electrode laid out of the lens to detect
electrochemical signals in response to glucose [68]. Another design included integration of an electrical
circuit, a sensing probe, a body-wired communication transmitter, a power supply, and a PDMS contact
lens by using MEMS techniques. During the monitoring, the glucose solution was orally administrated
to rabbits and the BG level was measured using a glucose monitoring kit (Figure 5). This biosensor
showed rapid responses to glucose and an appropriate calibration range (0.03–5.0 mM), which covered
the reported tear glucose levels [69].
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Spectral sensors for CGM, on the other hand, were simplified. Contact glucose-sensing lenses based
on hydrogels that contain phenylboronic acid (PBA) and photonic crystals that function without requiring
power were proposed [70–72]. Such soft hydrogel lenses embedded an array of mono-disperse particles,
which could diffract electromagnetic waves according to Bragg’s law. It is well known that PBA-modified
hydrogels are able to bind cis-diols in glucose, leading to volumetric changes and forcing the lens to
expel water, altering the array spacing, thus changing the perceived color of the lens. Moreover, the color
changes caused by the reaction are quick and reversible. Other photonic crystal embedded lenses were
developed to improve the sensitivity or use different detection spectrometers [73,74]. Recently, a plastic
contact lens outfitted with a physically gelated photonic crystal hydrogel was synthesized for CGM
in our group. The hydrogel was physically crosslinked from PVA-PEG system, which could offer
an anti-fouling layer for the penetration of glucose. This hydrogel was subsequently modified with
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4-boronobenzaldehyde, inproving the sensitivity for glucose, and a prototype of such a lens is shown in
Figure 6a. The sensing behavior of the lens was monitored by a reflection photospectrometer, and the
results showed that the diffracted wavelength was relatively shifted with the increasing glucose
concentration in artificial tear solution (Figure 6b). Despite the exciting design, it remains difficult
to measure glucose concentrations in tears using contact lenses. Because of the very low amount of
glucose present in healthy control subjects (3.59 mM) and for diabetic subjects (4.69 mM), the tear
glucose levels measured appear to vary with the volume of the aqueous tear fraction collected.
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3.2. Salivary Biosensors
Many authors have found higher glucose salivary levels in diabetic patients than in
non-diabetics [75–78]. Such investigations mainly aimed at exploring whether diabetic control could be
monitored by a non-invasive salivary glucose measurement method. Saliva is a great diagnostic fluid
providing an alternative to direct blood analysis via the permeation of blood constituents without any
skin-piercing for blood sampling [79]. Actually, saliva glucose concentrations range approximately from
20 to 200 mmol/L in normal and diabetic individuals, and closely follow circadian BG fluctuations [80].
Saliva and BG levels correlate reasonably well in a sample of individuals [81–83], however, a much
stronger correlation is observed within the same individual, enabling BG concentrations to be estimated
from saliva glucose measurements [84].
Various attempts have been made by researchers to develop glucose monitoring systems for
salivary measurements. Lambert et al. used conventional measurement through colorimetric assays [85].
Lipson et al. detected the saliva glucose level through NIR/Raman-based spectroscopic techniques [86],
and Yamaguchi et al. used Clarke-type electrode-based amperometric measurements, etc. [80]. Taking clues
from these developments, Soni et al. developed an optical biosensor for direct determination of salivary
glucose by using glucose oxidase enzyme immobilized on filter paper strips (specific activity 1.4 U/strip)
and then reacting it with synthetic glucose samples in the presence of a co-immobilized color pH
indicator [83]. The filter paper changed color based on the concentration of glucose in the reaction
medium and hence, by scanning this color change (using RGB profiling) through an office scanner
and using open source image processing software (GIMP), the concentration of glucose in the reaction
medium could be deduced.
Wearable sensors have recently attracted considerable interest owing to their promise for real-time
monitoring of the wearer’s health and fitness in a wide range of biomedical, sport and military
scenarios [87,88]. Recent efforts have led to wearable biosensors for detecting chemical biomarkers
in human fluids that can be obtained non-invasively, e.g., tears, sweat or saliva [89–92]. Kim et al.
reported a mouth-guard biosensor for continuous monitoring of salivary lactate and other chemical
components [79,93]. A mouth-guard glucose sensor produced using micro electromechanical systems
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(MEMS) techniques would offer promise as a minimally-invasive, painless, continuous, custom-fitted
and wireless solution for self-monitoring of glucose. Mitsubayashi et al. have developed a detachable
“Cavitas sensor” used in the human oral cavity for non-invasive monitoring of saliva glucose [94],
as shown in Figure 7. The mouth-guard glucose sensor consisted of a platinum and silver/silver
chloride electrode, with glucose oxidase immobilized by entrapment with poly(MPC-co-EHMA)
(PMEH), on a custom-fitted monolithic mouth-guard support with a wireless transmitter, thereby
enabling telemetric measurement of saliva glucose.
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conventional glucose sensors, optical sensors benefit from the absence of electromagnetic 
interference, simple design and handling as well as low cost. Miniaturization of optical sensors is 
easily achievable without compromising performance and dramatically reduces repulsion reactions. 
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Figure 7. (A) Schematic image of the glucose biosensor on the polyethylene terephthalate glycol
mouthguard support. Pt and Ag electrodes were formed on the PETG through a sputtering process.
Each electrode sensor consisted of a 0.20 mm2 Pt working electrode and a 4.0 mm2 Ag/AgCl
reference/counter electrode, both insulated with PDMS on a 0.5 mm thick PETG layer. 30 units of GOD
were applied to the sensing region of the working electrode. In order to optimize enzyme entrapment,
2.0 mL of 1.0 wt% PMEH solution was spread over the sensing region to form the PMEH overcoat;
(B) Schematic image of the mouth-guard biosensor custom-fit to the patient’s dentition. The device
consists of a glucose sensor and wireless transmitter incorporating a potentiostat for stable glucose
measurement. The sensor was designed to fit the mandibular dentition from the first premolar up
to the third molar. T e wireless transmitter was neatly encased in PETG. Reprinted with permission
from [94].
3.3. ther ethods
ece tly continuous glucose monitoring devices have become available and could provide more
detailed data on glucose excursions. In future applications such continuous gl cose sensors may
become a critical component of closed loop insulin delivery systems and, as such, must be selective,
rapid, predictable an acceptable for continuous patient se. Many potential sensing modalities are
being pursued for this, inclu ing optical techniques.
tical sensors se light of variable freq encies to etect gl cose, tilizing ifferent interaction
ro erties of light ith gl cose olec les in a concentration- e en ent anner [95]. o are to
conventional glucose sensors, optical sensors benefit from the absence of electromagnetic interference,
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simple design and handling as well as low cost. Miniaturization of optical sensors is easily achievable
without compromising performance and dramatically reduces repulsion reactions. Evidently, optical
sensing technology can provide an interesting alternative to more established electrochemical sensors
and will contribute to better flexibility concerning the design of CGM systems, their cost, materials
used, etc. [96]. Based on this optical transducing technology, numerous optics-based CGM systems
have been developed, such as fluorescence, infrared absorption spectroscopy, and Raman spectroscopy.
Fluorescence uses the principle of varying light emission from molecules in different states. It is
fast, reagentless and extremely sensitive. Many fluorescence-based glucose sensors are based upon the
affinity sensor principle where glucose and a fluorescein-labelled analogue bind competitively with
a receptor site specific for both ligands [97,98]. Other fluorescence techniques use enzyme- catalysed
reactions to change fluorescent status. Fluorescein may be bound to glucose oxidase, allowing energy
transfer between the flavin group of GOx and the fluorescein. The GOx enzyme may be further
utilized by measuring oxygen consumption or hydrogen peroxide production by fluorescence [99,100].
GOx can also be used as glucose-binding protein, utilizing its intrinsic fluorescent properties and may
be used without its flavin group with a fluorescent label [101].
Near infrared (NIR) light (wavelength 0.7–1.4 µm) provides an optical window in which 90%–95%
of light passes through the stratum corneum and epidermis into the subcutaneous space independent
of skin pigmentation. It is already successfully used to non-invasively monitor the concentration of
oxygenated and deoxygenated haemoglobin in the preterm infant brain [102]. BG has been measured
across the oral mucosa using NIR [103]. The oral mucosa is an obvious candidate for sensing, as it
is well vascularized and may be trans-illuminated. However, any oral measurement includes saliva,
which may contain a different glucose concentration, and residual food may contain interferents.
NIR spectroscopy has been measured across the tongue [104]. The standard error of prediction was
3.5 mmol/L, with significant variability caused by variability in tissue fat. NIR therefore ideally
requires consistent tissue fat in addition to a path length in the order of 5 mm [105]. In order to solve
some of the problems posed by transdermal optical techniques, NIR has been proposed in combination
with techniques for sampling ISF, including sonophoresis [106].
Raman spectroscopy assesses scattering of single wavelength light. This is dependent on rotational
or vibrational energy states within a molecule and highly specific absorption bands are seen with
Raman spectroscopy which can be used to identify and quantify molecules. It has the benefit of
reduced interference from water compared with MIR or NIR spectroscopy. However, the Raman
signal is weaker than that of other technologies, requiring powerful detectors for physiological
concentrations of glucose. The Raman signal is also susceptible to turbidity, haematocrit, skin thickness
and melanin. Sufficient sensitivity can be achieved by surface-enhanced Raman spectroscopy (SERS).
The electromagnetic mechanism of SERS is that when an electromagnetic wave interacts with a metal
surface, the fields at the surface are different than those observed in the far field. If the surface is
rough, the wave may excite localized surface plasmons on the surface, resulting in amplification of
the electromagnetic fields near the surface. If one assumes that there is enhancement of the intensity
of the incident and scattered fields (albeit at different wavelengths), then the possibility of a large
enhancement of Raman scattering intensity arises [107]. And now some reports utilized the SERS
signal probes served as the molecular recognition agent in response to the concentration of glucose.
Torul et al. fabricated a SERS substrate by modifying two component self-assembled monolayers
(SAMS) on the surface of gold nanorod particles [108]. The variation of the SERS signal of SAMS
showed the response to the concentration of glucose, and a low detection limit of 0.5 mM was obtained.
Kong et al. proposed a novel glucose binding mechanism by using phenylboronic acid as the receptor
for saccharide and forming a glucose-alkyne-boronic acid complex on SERS substrate, which exhibited
a new Raman peak at 1996 cm−1 [109]. Thus, the novel technology offered a high sensitivity for SERS
glucose sensing.
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4. Future Perspectives
The worldwide increase in the number of diabetic patients has encouraged scientists to put great
efforts into the field of continuous glucose monitoring (CGM) devices, which would dramatically alter
the treatment of diabetes as well as the life quality of diabetic patients. So far, there are only a few
commercial CGM devices, developed by Medtronic (Minneapolis, MN, USA) and Dexcom, which have
been approved by the FDA and their current lifetimes are less than one week. No commercial CGM
devices are available for long-term monitoring, however, it is extremely important for T1D, which
accounts for around 10% of diabetic patients. The existing studies of long-term mini-invasive biosensors
remain challenging, mainly due to the foreign body responses such as biofouling, fibrous capsule
and inflammation. To overcome foreign body responses and improve the life-time of implantable
biosensors, we believe the following issues should be addressed: (1) improving the loading amount
and stability of enzymes. The coil type electrode design is one way to load more enzyme to reduce
the effects from accumulation of H2O2, glucose oxidase molecular cloning or encapsulation in silica
sol-gel may be another way to reduce the degradation of cross-linked enzymes [110]; (2) a number
of interferences (e.g., acetaminophen, ascorbic acid, and uric acid) can affect sensor response as they
are electroactive during the oxidation of hydrogen peroxide, although semi-permeable membranes
with designed porosity, like polyurethane, are able to alleviate this effect, At the meantime, decreasing
the work potential through electrode design is another route to reduce interference; (3) to reduce
foreign body responses once the biosensors are implanted, the synthesis of anti-fouling films is
a common strategy to improve glucose sensor functionality against the initial adhesion of proteins.
The introducing of biocompatible hydrogel coatings or collagen encapsulation for sensing devices are
other key approaches to improve the lifetime. The use of small anti-inflammatory and/or antigenic
molecules, such as dexamethasone, to influence tissue integration has been intensively studied. Here,
the drug delivery system with biocompatible and controllable particles, like poly(lactic-co-glycolic acid)
is pursued to limit inflammation and take advantage of the wound healing properties of this material.
Despite the fact that the results from non-invasive devices require frequent calibration against
invasive ones, the innovative design might be an alternative choice for glucose measurements than
traditional implanted electrochemical biosensors. Two possible techniques have the most chance
for non-invasive glucose monitoring, one is tear glucose sensors and another is salivary biosensors.
Detecting glucose in tear fluid has been established for over twenty years, and the major challenge
for traditional contact lens biosensors is that the amount tear fluid is not high enough to cover the
electrode to construct an electrochemical cell, and this thus leads to less accuracy in this type of
sensor. Compared with electrochemical sensors, a plastic contact lens outfitted with a physically
gelated photonic crystal hydrogel maybe a possible route for CGM in the future. A salivary biosensor
incorporating Pt and Ag/AgCl electrodes on a mouth-guard support as dental material with an enzyme
membrane was developed and tested by Mitsubayashi’s group [94], and this invisible mouth-guard
biosensor integrated with a low energy wireless module could be an ideal candidate for future real-time
monitoring of salivary glucose levels.
Non-enzymatic sensor show enhanced sensitivity and detection limits, while avoiding the
expensive and fragile enzymes in the system, and thus it is also a promising choice for the next
generation of CGM. Although there are large number of research work on this area, the clinic products
are not yet available in the market. The ultimate goal for treating diabetic patients is to construct an
artificial pancreas, combining CGM and insulin dosage system, the life time of CGM is the greatest
challenge, and are required for deeply and comprehensively studied in the future.
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